M. Şendur

发表

The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

A. Bilici, Yakup İriağaç, S. Paydaş, 2021, Journal of Cancer Research and Clinical Oncology.

The Real-Life Efficacy of the Second Line Treatment Strategy in Advanced Pancreas Cancer

B. Öksüzoğlu, B. Yalcin, E. Esin, 2022, Journal of Oncological Sciences.

Clinicopathological Factors in Relation to HER2 Status in Metastatic Gastric Cancer: A Retrospective Observational Study

B. Savaş, E. Akkuş, N. Karadurmuş, 2022, Journal of Oncological Sciences.

Prognostic Importance of Albumin Globulin Ratio in Small Cell Lung Cancer

B. Yalcin, B. Bilgin, Ş. Yücel, 2019, Ankara Medical Journal.

Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)

M. Dogan, E. Çavdar, Feyza Firat, 2022, Turkish journal of medical sciences.

Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study

S. Kılıçkap, H. Coşkun, M. Artaç, 2022, European Journal of Clinical Pharmacology.

First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

T. Kaçan, M. Karaağaç, S. Kılıçkap, 2022, Bosnian journal of basic medical sciences.

Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group

A. Bilici, S. Paydaş, E. Akkuş, 2022, Medicine.

Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

A. Erdoğan, A. Bilici, D. Erdem, 2022, Journal of Cancer Research and Clinical Oncology.

Lung Cancer in Turkey.

S. Sak, A. Eroğlu, A. Cangır, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

A. Bilici, S. Paydaş, A. Bahceci, 2021, Journal of Cancer Research and Clinical Oncology.

The Efficacy and Safety of Treatment Regimens Used in the First-Line Setting in Metastatic Pancreatic Cancer Patients

M. Küçüköner, S. Kılıçkap, M. Kaplan, 2022, Pancreas.

Major and minor salivary gland cancers: A multicenter retrospective study

H. Harputluoglu, O. Yazıcı, M. Gumus, 2023, Head & neck.

The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

D. Erdem, D. Aydın, B. Yalcin, 2022, Journal of Cancer Research and Clinical Oncology.

Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study

H. Harputluoglu, U. Demirci, A. Bilici, 2023, Acta oncologica.

Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

H. Harputluoglu, A. Bilici, M. Gumus, 2022, Journal of Clinical Oncology.

Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study

A. Bilici, I. Çiçin, K. Helvacı, 2023, Biomolecules and biomedicine.

The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

D. Erdem, D. Aydın, B. Yalcin, 2022, Journal of Cancer Research and Clinical Oncology.

Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium

B. Öksüzoğlu, M. Özgüroğlu, S. Kılıçkap, 2023, Urologia Internationalis.

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Ö. Acar, A. Erdoğan, Kubilay Karaboyun, 2023, BMC Cancer.

124P Talazoparib in locally advanced or metastatic breast cancer patients: Experience from an early access program in Turkey

S. Paydaş, E. Gokmen, D. Erdem, 2021 .

Immunotherapy for Lung Cancer

E. Göker, N. Akyürek, N. Karadurmuş, 2023, Journal of Oncological Sciences.

Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group.

E. Göker, S. Kılıçkap, B. Oyan, 2023, Current problems in cancer.

H. Kara, B. Yalcin, N. Uğurlu, 2023, Cutaneous and ocular toxicology.

Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG).

U. Kefeli, S. Kılıçkap, P. Yumuk, 2024, Clinical genitourinary cancer.

Is fibroblast growth factor 11 (FGF11) a predictive marker for breast cancer?

Ş. Karabulut, D. Uncu, M. Şendur, 2024, Medicine.

First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.

S. Park, A. Balar, M. Gumus, 2022, Journal of Clinical Oncology.

Palbociclib in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer: A Systematic Scoping Review of Real-World Evidence from Countries Outside of Western Regions that Are Underrepresented in Clinical Trials

M. Şendur, Amit Rauthan, Ankita Jain, 2024, Oncology and therapy.

Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.

A. Balar, R. de Wit, P. Grivas, 2023, European urology.

Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study

U. Demirci, A. Kargi, H. Turna, 2024, Current medical research and opinion.

The Efficacy and Safety of Treatment Regimens Used in the First-Line Setting in Metastatic Pancreatic Cancer Patients

M. Küçüköner, S. Kılıçkap, M. Kaplan, 2021, Pancreas.

Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience

Recep Ak, N. Karadurmuş, S. Kahraman, 2023, Journal of Oncological Sciences.

Demographic Characteristics and Treatment Outcomes of Patients with Renal Cell Cancer: Single Center Experience

A. Ulaş, B. Yalcin, B. Bilgin, 2016 .